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Desensitization to carboplatin in low- grade glioma. A revision 
of 100 treatments in children
To the Editor,
Hypersensitivity reactions (HSR) in children during chemotherapy 
have been increasingly documented.1
Rapid drug desensitization (RDD) is practically unknown to most 
oncologists despite allowing patients to be treated with first- line 
agents. In pediatric age, there is a lack of guidelines and general prin-
ciples have been adapted from adults (Figure 1).
Carboplatin is used for the treatment of a wide range of tumors, 
and the combination with vincristine is the most widely adopted 
scheme for childhood low- grade glioma (LGG).2
The aim of this letter is to report a 10- year period of experience 
with RDD to carboplatin in children diagnosed with LGG in a tertiary 
hospital.
Clinical records of children submitted to RDD to carboplatin be-
tween July 2009 and April 2019 were reviewed.
Skin prick tests (10 mg/mL) and intradermal tests (1 and 10 mg/
mL) with carboplatin were performed according to international 
recommendations.3 To minimize pain, a prilocaine- lidocaine patch 
(EMLA®) was applied 30- 60 minutes before.
In all cases, the decision to proceed to RDD was based on a 
strong clinical suspicion of HSR plus the absence of an equally safe 
and effective alternative treatment.
In all cases, the family was informed about the risk- benefits of 
this procedure. Motivation and ability to collaborate were assessed. 
It should be noted that in no case, the lack of family support re-
strained the protocol; hospital settings and therapeutic schedule 
were adapted in case of family limitations.
All patients were desensitized under close supervision of aller-
gists. In milder cases, RDDs were performed in the pediatric oncol-
ogy day hospital/pediatric ward. In cases of anaphylaxis, the first 
RDD was performed in the intensive care unit. In the absence of 
breakthrough reactions (BR), subsequent treatments were moved to 
usual facilities.
Until 2011, an adapted Cofino- Cohen protocol was applied;4 
subsequently, the protocol developed by Castells3 was used.
Protocols were designed according to the intended cumulative 
dose and severity of the IR (“tailor- made”). A 12- step protocol with 3 
parental preparations with progressive concentrations at incremen-
tal rates was initially performed. The usual protocol included pre- 
medication with antihistamine and methylprednisolone (1 mg/kg) 
1 hour before the infusion, intravenous hydration, and ondansetron.
If needed, adaptations of the initial protocol, including the ad-
dition of several intermediate steps and even of a fourth bag, were 
performed as well as a pre- medication reinforcement.
A total of 48 patients received intravenous carboplatin for LGG, 
and 15 had a reaction compatible with an IgE- mediated HSR (inci-
dence of 31%).
All were being treated with carboplatin (550 mg/m2) plus 
vincristine. The median age at the IR was 3 years old (range, 
18 months- 9 years old) (Table 1). A median of 8 cycles of carbo-
platin was performed until the IR, the majority starting <30 min-
utes after infusion (all within 1h). The clinical pattern varied from 
moderate (isolated mucocutaneous symptoms in 6 cases) to severe 
(9 anaphylactic reactions). Acute and baseline tryptase was mea-
sured in only 5 of 9 patients with anaphylaxis and was elevated 
(baseline tryptase × 1.2 + 2 ng/ml) in 3. Only one patient received 
epinephrine.
Skin tests (ST) were negative in the 4 tested patients.
No schedule delays due to desensitizations procedures occurred.
In total, 100 RDDs to carboplatin were performed with a median 
of 6.7 treatments per patient. In 6 patients, RDDs were successful in 
the first treatment, and in 9 patients (60%), adaptations to the initial 
protocol and reinforcement of pre- medication were performed (an-
tihistamines, corticosteroids, and montelukast). The BR were more 
severe than the initial reaction in 4 patients.
In the majority of cases (78%), BR were successfully managed by 
discontinuing the infusion and administering rescue medication; the 
infusion was only restarted once the symptoms resolved.
In 2 patients, the RDDs were unsuccessful due to severe BR de-
spite adaptations and an alternative drug was used.
DISCUSSION
Literature data on carboplatin HSR in children with LGG are limited. 
The higher rate of HSR was found in the cohort of Dudgshun et al5 
and the frequency differed according to the protocol used; 8% of pa-
tients treated with only carboplatin and 68% of those with combined 
carboplatin and vincristine presented HSR, respectively. An immune 
potentiating effect of the association of the drugs was hypothesized. 
In our study, all patients were treated with carboplatin and vincris-
tine but our rate of HSR was significantly lower. Our study did not 
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include patients that tolerated subsequent infusions after preven-
tive measures were started, and this may explain the results´ dif-
ference as only one- third of Dodgshun´s patients were desensitized 
with carboplatin.
In accordance with previous studies, the reactions begun at the 
eighth cycle; the risk of hypersensitivity to carboplatin seems to be 
related to the cumulative number of exposures rather than to the 
cumulative dose itself.1,3,6,7
Anaphylaxis represented 60% of the IR, in agreement with the 
literature which reports that most of platinum HSR are severe.8
Only one patient was treated with adrenaline, which emphasizes 
the worldwide reality in which anaphylaxis is often under recognized 
and under- treated.9
ST to carboplatin have been recommended between the fifth and 
eighth cycle in order to predict the risk of future HSR.10 However, 
the implications of a positive test are not clear, especially in children. 
The young age and the fragility of these patients also justified skip-
ping this prophylactic ST in our children.
Diagnostic ST to carboplatin were not performed in every pa-
tient as the optimal timing could imply a treatment delay. Of the 
4 patients tested, none had positive ST. Non- irritative concentra-
tions are only validated in adults and children may behave differ-
ently and display positive results less frequently or with different 
concentrations.11 Validation of ST with EMLA® with other drugs 
found no differences in ST results but platins were not evaluated 
in this study.12
F I G U R E  1  For understanding purpose, an adapted protocol was adjusted according to 2 hypothetical scenarios, based on our patients
Main protocol for 407 mg carboplatin desensitization
Step Solution Rate (ml/h) 
Time 
(min) 
Volume 
(mL) 
Dose 
(mg) 
Cumulative 
Dose (mg) 
1 A 2 15 0.5 0.01 0.01 
2 A 5 15 1.25 0.025 0.035 
3 A 10 15 2.5 0.05 0.085 
4 A 20 15 5 0.1 0.185 
5 B 5 15 1.25 0.25 0.435 
6 B 10 15 2.5 0.5 0.935 
7 B 20 15 5 1 1.935 
8 B 40 15 10 2 3.935 
9 C 10 15 2.5 5 8.935 
10 C 20 15 5 10 18.935 
11 C 40 15 10 20 38.935 
12 C 80 145 193.5 387 407 
Solution Total Volume Concentration Dose
Solution A 250 mL 0.02 mg/mL 5 mg 
Solution B 250 mL 0.2 mg/mL 50 mg 
Solution C 250 mL 2 mg/mL 500 mg 
Scenario 1. Recurrent generalized urticaria at the 9h step requiring
An additional step was added 
antihistamines and corticosteroids. 
Step Solution Rate (ml/h) 
Time 
(min) 
Volume 
(mL) 
Dose 
(mg) 
Cumulative 
Dose (mg) 
1 A 2 15 0.5 0.01 0.01 
2 A 5 15 1.25 0.025 0.035 
3 A 10 15 2.5 0.05 0.085 
4 A 20 15 5 0.1 0.185 
5 B 5 15 1.25 0.25 0.435 
6 B 10 15 2.5 0.5 0.935 
7 B 20 15 5 1 1.935 
8 B 40 15 10 2 3.935 
9 C 5 15 1.25 2.5 6.435 
10 C 10 15 2.5 5 11.435
11 C 20 15 5 10 21.435
12 C 40 15 10 20 41.435
13 C 80 137 182.8 365.6 407 
Solution Total Volume Concentration Dose
Solution A 250 mL 0.02 mg/mL 5 mg 
Solution B 250 mL 0.2 mg/mL 50 mg 
Solution C 250 mL 2 mg/mL 500 mg
Scenario 2. Anaphylaxis at the 3
bag was added. 
rd step. An additional 
Solution Total Volume Concentration Dose
Solution A 250 mL 0.002 mg/mL 0.5 mg
Solution B 250 mL 0.02 mg/mL 5 mg
Solution C 250 mL 0.2 mg/mL 50 mg 
Solution D 250 mL 2 mg/mL 500 mg
Step Solution Rate (ml/h) 
Time 
(min) 
Volume 
(mL) 
Dose 
(mg) 
Cumulative 
Dose (mg) 
1 A 2 15 0,5 0,001 0.001 
2 A 5 15 1,25 0.0025 0.0035 
3 A 10 15 2,5 0.005 0.0085 
4 A 20 15 5 0.01 0.0185 
5 B 5 15 1,25 0.025 0.0435 
6 B 10 15 2,5 0.05 0.0935 
7 B 20 15 5 0.1 0.1935 
8 B 40 15 10 0.2 0.3935 
9 C 10 15 2,5 0.5 0.8935 
10 C 20 15 5 1 1.8935 
11 C 40 15 10 2 3.8935 
12 C 80 15 20 4 7.8935 
13 D 20 15 5 10 17.8935 
14 D 40 15 10 20 37.8935 
15 D 80 15 20 40 77.8935 
16 D 100 99 164,6 329,1 407 
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Although none of the suspected HSR was confirmed by ST, the 
high rate of BR during RDD (60%) corroborates the initial diagnosis.
Only 2 patients (13%) failed RDD. They had bothersome symp-
toms that persisted or even worsen with RDD despite several modi-
fications to the initial protocol.
BR during RDD were more severe than the IR in 4 cases; a more 
accurate characterization of the reactions by allergists might be an 
explanation.
The success rate of RDD to carboplatin in this study was 87%, 
comparable to rates3 in adult series, but significantly different from 
some of pediatric series with higher success rates observed in milder 
reactions or lower carboplatin doses.1,5- 7,11
The SIOP guidelines2 discourages RDD to carboplatin; never-
theless, RDD has been successfully performed in our department 
as in several other centers.4,6,7,11 However, the high rate of severe 
reactions during RDD highlights the importance of such procedures 
to take place under the supervision of an allergist, in a pediatric on-
cology center.
RDD was performed even in infants that achieved several years 
of survival after treatment. Two patients (4 and 5) died after treat-
ment conclusion due to disease progression.
Limitations of the study include the small number of patients 
and the absence of all data in some patients due to its retrospective 
nature.
In conclusion, clinicians must not underestimate the potential 
risk of HSR to chemotherapy in children. However, RDDs performed 
under suitable conditions can be an option for these patients, im-
proving the final oncologic outcome. To our knowledge, this is the 
biggest case series on desensitization to carboplatin in children.
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